1. Introduction {#s0005}
===============

Myofibrillar myopathy (MFM) is a clinically and genetically heterogeneous group of disorders characterized by myofibrillar disorganization and the presence of ectopic protein aggregates in skeletal muscle. The dissolution of myofibrils commences at the Z-disk. Abnormal expression of desmin (*DES*), myotilin (*MYOT*), αB-crystallin (*CRYAB* or *HSPB5*) and dystrophin (*DMD*) results in accumulation of degraded filamentous material in various patterns mostly in myofibril-free fiber regions around nuclei and under the sarcolemma. Membranous organelles are dislocated and their degradation in autophagic vacuoles can be also observed [@bb0005].

The clinical features of MFM are diverse. Patients usually present with slowly progressive muscle weakness that often begins in distal muscles and spreads proximally, but an early limb-girdle involvement can also occur. Cardiomyopathy is an associated symptom in 15--30% of cases [@bb0010]. The patients may also display remarkably different clinical manifestations and extra-muscular involvement, including autosomal dominant congenital posterior pole cataract (CPPC) in some families with neither cardiac nor muscular phenotype reported [@bb0015]. The age at onset ranges from infancy to the eighth decade of life, however, the majority of MFM begins in the fourth and fifth decades [@bb0020]. Due to the associated phenotypic features, and pathomorphological heterogeneity, the differential diagnosis between MFM and other late-onset myopathies with a predominantly distal distribution presents a clinical challenge.

A growing number of genes have been associated with MFM pathogenesis, causing subtypes of the disease [@bb0005]. So far nine MFM-causing genes encoding Z-disc associated proteins have been identified: *DES*, *CRYAB*, *MYOT*, Z band alternatively spliced PDZ-containing protein (*ZASP*), filamin C (*FLNC*), Bcl2-associated athanogene-3 (*BAG3*), four-and-a-half LIM protein-1 (*FHL1*), titin (*TTN*) and sarcomeric actin (*ACTA1*) ( see [@bb0025] for review). MFM is usually transmitted in an autosomal dominant manner, however, autosomal recessive or X-linked MFM forms have also been described [@bb0030]. So far thirteen different *CRYAB* mutations were identified not only in isolated cases of MFM, but also in association with congenital cataract, cardiomyopathy and multisystemic phenotypes involving some or all of the above traits [@bb0035], [@bb0040], [@bb0045].

The *CRYAB* gene maps to 11q23.1, comprises 3 exons spanning 3.2 kb, and encodes a 175-amino-acid protein with a molecular mass of \~ 20 kD [@bb0050]. The CRYAB protein (also called HSPB5) belongs to the ATP-independent HSPB family (small HSP), characterized by a conserved α-crystalline domain [@bb0055]. It was initially identified as one of the structural proteins of the eye lens, however, it is widely expressed in many tissues and organs, including skeletal and cardiac muscle. *CRYAB* upregulation has been linked with a variety of diseases depending on the tissue [@bb0060], [@bb0065]. It is involved in many processes including prevention of abnormal folding of other proteins, cytoskeletal formation, apoptosis inhibition, and modulation of membrane fluidity [@bb0070]. In the muscle CRYAB functions as a chaperone in cytoskeletal intermediate filament assembly and stabilization [@bb0075], [@bb0080], [@bb0085]. In addition, CRYAB plays a role in the mammalian RNAi/microRNA pathway, modulating the Ago2/RISC activity and as a result cellular homeostasis in the skeletal muscle [@bb0090].

Cells expressing mutated *CRYAB* are characterized by protein aggregates of primarily the mutant CRYAB. HSPB family members form homo- and hetero-oligomeric complexes with other HSPBs, playing a key role in substrate recognition and chaperoning functions, resulting in differential clinical manifestation of various *CRYAB* mutations [@bb0095]. It remains unresolved whether aggregates of the CRYAB itself are associated with a gain-of-toxic mechanisms or loss of function.

Here, we report the first Polish female patient with MFM clinical diagnosis and a novel dominant *CRYAB* mutation, and we propose a model presenting the deleterious effect of the mutation on the protein structure and function.

2. Materials and methods {#s0010}
========================

2.1. Genetic analyses {#s0015}
---------------------

DNA was extracted from the peripheral blood of the proband using standard methods. Whole exome sequencing (WES) was performed commercially at the BGI Tech Solutions (Hong Kong) using SureSelect Human All Exon v5 + UTR enrichment kit and paired-end 100 nt sequencing on the Illumina HiSeq2000 platform. Fastq read files were generated from the sequencing platform via the Illumina pipeline. Adapter sequences in the raw data were removed and low quality reads with low base quality were discarded. In total, 240.451.900 "clean" paired-end reads were aligned to the human hg19 reference genome using Burrows-Wheeler Alignment (BWA) package [@bb0100]. Duplicate reads were removed with Picard and base quality Phred scores were recalibrated using GATK\'s covariance recalibration [@bb0105]. The 15 GB of aligned sequence data resulted in 99 × median coverage of the target capture regions with 99.6% of target bases covered at least 10 ×. Alignments were viewed with Integrative Genomics Viewer [@bb0110]. SNP and indel variants were called using the GATK Unified Genotyper. Annovar was used for initial variant annotation [@bb0115] with further annotation, filtering and analysis performed on Galaxy platform (on PL-Grid Infrastructure). Selected mutations were confirmed using a direct fluorescence-based sequencing (ABI 3130 Genetic Analyzer, Applied Biosystems, USA).

2.2. Muscle biopsy {#s0020}
------------------

The open muscle biopsy of the proband\'s biceps brachii was performed, and the muscle specimen was processed for further analyses.

2.3. Light and fluorescence microscopy {#s0025}
--------------------------------------

Histological and histochemical evaluation was performed using a routine battery of methods. Immunohistochemistry was performed using rabbit polyclonal anti-CRYAB antibody (Medac GMBH, Germany) at 1:100 dilution.

2.4. Electron microscopy analysis of the muscle biopsy {#s0030}
------------------------------------------------------

Analysis was performed using standard methods*.* For electron microscopy analysis, a fragment of the muscle specimen was fixed in glutaraldehyde, post fixed in osmium tetroxide and then embedded in Spurr embedding medium (Electron Microscopy Sciences, USA). Ultrathin sections of the selected areas were stained with uranyl acetate and counterstained with lead citrate. The samples were viewed using a JEM 1200 EX2 electron microscope.

2.5. Molecular modeling {#s0035}
-----------------------

### 2.5.1. System preparation {#s0040}

The 24-mer oligomeric structure of human CRYAB was downloaded from the Protein Data Bank (PDB code [2YGD](pdb:2YGD){#ir0005}) [@bb0120]. Only first six monomers (chains A to F), which create the symmetrical circular structure, were taken for the simulation. Three different *CRYAB* variants were investigated: the native protein, novel mutation D109A and previously described mutation affecting the same residue: D109H. The mutated histidine was used in neutral form as it was assumed for other histidine residues in the oligomer. D109 residue was mutated in all six monomers in the oligomer. All energy minimizations, equilibrations and molecular dynamics (MD) simulations were carried out in the NAMD program version 2.10 [@bb0125] using the CHARMM27 for protein force field [@bb0130]. Additionally, instead of explicit water molecules, the implicit solvent method was applied.

### 2.5.2. Molecular Dynamics (MD) simulations {#s0045}

Each structure of oligomeric CRYAB was initially subjected to 10,000 steps of energy minimization and then 100 ns MD equilibration with increasing temperature from 20 K to 298 K in the first steps of MD: 1 K per 1 step. The MD simulations were performed using Langevin (stochastic) dynamics [@bb0135], which is a default in the NAMD program for implicit solvent method. In Langevin dynamics the molecules interact with a stochastic heat bath via random and dissipative forces. The friction coefficient of 50 ps^− 1^ was used and temperature was set to 298 K. For the van der Waals and electrostatic interactions a cutoff of 14 Å was used with a switching function for soft dampening the remaining interactions. For each investigated system 100 ns MD simulation was performed with a time step of 1 fs. All figures of molecular structures were created using the VMD program (v.1.9.2) [@bb0140].

2.6. Ethics statement {#s0050}
---------------------

Written consent was obtained from all patients and healthy individuals according to the Declaration of Helsinki. The study was approved by the Ethics Committee of the Warsaw Medical University and the MSW Hospital (Warszawa, Poland) in compliance with the national legislation and the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association.

3. Results {#s0055}
==========

3.1. Case description {#s0060}
---------------------

Fig. 1Analysis of the proband\'s muscle. A) Hematoxylin/eosin (HE) staining; B) Trichrome staining; C) Succinate dehydrogenase (SDH) staining; D) and E) Electron micrographs; and F) Immunostaining with anti-CRYAB antibody. Arrows in A) and B) point at the dark material; in C) point to lobulated fibers, and in D) and E) point to electron dense material. Bars: 10 μm in A--C and F, and 500 nm in D and E.Fig. 1.

Neurological examinations of the proband revealed nasal speech, dysphagia, high arched palate, significant weakness and wasting of the upper limbs muscles, mostly pronounced in the proximal part of the limbs. Deep tendon reflexes were diminished in the upper and lower limbs. In the lower limbs patient was able to move only her feet. At the age of 56 years. chronic respiratory failure was diagnosed and the patient is (to date) on nocturnal noninvasive ventilation. Chronic cardiac insufficiency was diagnosed at the age of 55 years. due to dilated cardiomiopathy. The biochemical and hematological parameters of the proband remains within normal limits except of elevation of serum creatine-kinase (CK) activity (81.39 IU).

The electromyogram (EMG), performed when the proband was 31 years old, showed myopathic features (decreased duration and size index of the motor unit action potentials, MUAP) were observed for the right first interosseous muscle as well as right vastus lateralis and tibialis anterior muscles. At the age of 52 years the results of the nerve conduction study were no different from normal subjects except for a decrease of M-response amplitude to right peroneal nerve stimulation (presumably due to atrophy of the muscle). CT scans of the lower limbs indicated complete muscle atrophy of both shins and thighs with relatively sparing of the adductors magnus and semimembranosus muscles.

In addition, among other symptoms the proband presented with cataract in the right eye, which was identified and operated at the age of 35 years. Fundus of the eye was normal. At that time, myotonic dystrophy was also suspected due to cataract and myopathy.

The morphological analysis of the muscle biopsy performed at 51 years showed moderate myopathic changes (see [Fig. 1](#f0005){ref-type="fig"}). The fascicular architecture of the muscle revealed a marked variability in fiber size and shape, with atrophy of some fibres, partially preserved as "nuclear clumps" ([Fig. 1](#f0005){ref-type="fig"}A-C). The presence of dark red material in hematoxylin/eosin (HE) staining ([Fig. 1](#f0005){ref-type="fig"}A, arrows) and dark blue material in trichrome staining ([Fig. 1](#f0005){ref-type="fig"}B, arrows) as well as of lobulated fibers in succinate dehydrogenase (SDH) staining ([Fig. 1](#f0005){ref-type="fig"}C, arrows) was observed.

Electron microscopy revealed profound changes in the fiber and sarcomer organization ([Fig. 1](#f0005){ref-type="fig"}D-E). In particular, disorganization of the sarcomers as well as the presence of electron dense material ([Fig. 1](#f0005){ref-type="fig"}D, arrows) was observed in the longitudinal sections. In addition, myelin figures and vacuolar structures were visible in the transverse sections, along with the electron dense material ([Fig. 1](#f0005){ref-type="fig"}E, arrows).

Immunohistochemistry using an anti-CRYAB antibody showed that unlike in normal muscle which show faint CRYAB positivity, especially at myomuscular and myotendinous junctions [@bb0145] but not at neuromuscular junctions CRYAB was located in aggregate-like structures distributed not only beneath the sarcolemma but also within the fibers, both in atrophic and normal-sized ones ([Fig. 1](#f0005){ref-type="fig"}F).

### 3.1.1. Proband\'s relatives {#s0065}

Proband\'s father (II.11, see [Suppl. Fig. 1](#f0015){ref-type="graphic"}) developed progressive lower limb weakness distal \> proximal (dropping feet) followed by difficulty climbing stairs at the age of 48 years. Neurological examination performed one year later revealed distal weakness and wasting of the upper and lower limbs. Deep tendon reflexes were diminished in the upper and lower limbs. Condition of the patient steadily deteriorated. The patient died at the age of 69 years.

Proband\'s uncle (II.3, see [Suppl. Fig. 1](#f0015){ref-type="graphic"}) developed slowly progressive distal weakness followed by proximal paresis at around 50 years of age. Cataract in both eyes was found and surgery was performed at the age of 53.

Proband\'s aunt (II.8, see [Suppl. Fig. 1](#f0015){ref-type="graphic"}) developed muscle weakness from distal part of the lower limbs (dropping feet) at around 40 years of age. She experienced cataract of both eyes and had surgery at the age of 45. Neurological examination performed at the age of 61 years revealed significant weakness and wasting of the upper as well as lower limbs muscles.

Moreover, the second proband\'s uncle (II.1) and aunt (II.10) showed similar symptoms, however, no detailed medical history is available. For a detailed comparison of the clinical characteristic of the affected family members of the proband see [Suppl. Table 1](#f0015){ref-type="graphic"}.

3.2. Genetic analyses {#s0070}
---------------------

Whole exome sequencing identified 126.804 SNPs and 23.284 InDels, of which 76.101 and 14.815 respectively were off target (defined as intergenic or intronic, but not affecting splice sites) and removed from further consideration.

Table 1Putative causative or phenotype-modifying genetic variants identified in the proband. SNVs and indels that passed initial filtering (Phred quality score of at least 30, missense/nonsense/indel mutations for coding sequences = MODERATE or HIGH impact) and filtering for "muscle weakness" in HPO terms related to the gene. cDNA and protein alterations are reported in the following transcripts: ENST00000460472 (*TTN*), ENST00000533475 (CRYAB), ENST00000337435 (NIPA1), ENST00000261866 (SPG11).Table 1ChrPositiondbSNPREFALTTypeImpactGeneHGVS.cHGVS.pGenotypeExAC MAFIn lab MAFMutation count2179597600rs72648937CTMissenseMODERATETTNc.15352G \> Ap.Val5118Methet0.005640.0214/1882179599667rs72648927GCMissenseMODERATETTNc.14033C \> Gp.Pro4678Arghet0.010620.0214/1884184596309rs140871779CTCIntronic/spliceLOWTRAPPC11het0.14670.06412/18811111779690.TGMissense/spliceMODERATECRYABc.326A \> Cp.Asp109Alahet--0.0051/1881468194090rs58392863AGADownstreamLOWZFYVE26het--0.0163/1881468233171.GAIntronic/spliceLOWZFYVE26het--0.0051/1881523086364rs531550505GGCCGInframe deletionMODERATENIPA1c.45_47delGGCp.Ala16delhet0.014420.14928/1881544907562rs111347025TCMissense/spliceMODERATESPG11c.3037A \> Gp.Lys1013Gluhet0.009930.0112/188[^2]

Fig. 2Circular hexamer of CRYAB. A) WT crystal structure. The particular monomers are colored yellow and green, alternatively. D109 residue is colored in purple and shown as balls. B), C) and D) CRYAB oligomeric structure after 600 ns of MD simulation. D109 residue is labeled in purple. Prim marked positions in adjacent monomer (in yellow). The structures: WT, D109H, and D109A, respectively. Mutations rearrange the network of local interactions (D109A to the largest extent) which leads to destabilization (partial unfolding) of monomer-monomer interfaces and in consequence to decreased stability of the whole oligomer.Fig. 2.Table 2Alignment of CRYAB amino acid sequence (*H. sapiens* positions: 98--120) with homologs\' sequences. Aspertic acid residue affected in the proband and its evolutionary conserved homologs marked in red.Table 2.

The D109A mutation was confirmed using a direct fluorescence-based sequencing in the proband. Every affected family members that was tested (III:20, II:3, II:8) harbored the mutation, and it was not present in the healthy family member (IV:7). The mutation was also absent in 86 ethnically matched exomes from our in-lab database.

3.3. Molecular modelling {#s0075}
------------------------

CRYAB is composed mostly of β-sheets and forms a large oligomeric structure. For the purpose of this research a hexamer (1050 residues) taken from 24-mer structure was used ([Fig. 2](#f0010){ref-type="fig"}A). This approach was used to increase statistical probability of finding an influence of a single mutation on the whole oligomeric structure of CRYAB, since there are six mutations in the structure and additionally the β-barrel-like structure of hexamer can be more sensitive to the possible changes introduced by the mutation. Each monomer is composed of a double β-sheet (larger and smaller with three β-threads in each) in form of a sandwich and a larger β-sheet of all monomers contributes to a central ring of oligomer. The primary, longer interface between monomers (residues 112--122) forms very strong intermolecular β-sheet, while the secondary interface in the β-barrel (residues 91--94) contains a large gap between β-threads so the intermolecular β-sheet is weak. This contact is mostly maintained by extended coiled-coil interactions by the rest of CRYAB structure.

In a wild type (WT) protein, the aspartic acid residue 109 (D109) forms hydrogen bonds and ionic interactions with adjacent residues, namely arginine 107 (R107) from the same monomer as well as with arginine 120 (R120′) and tyrosine 122 (Y122′) on the adjacent monomer. The interaction of R107 and R120 is stabilized by D80' from adjacent monomer, which closely interacts with both arginine residues ([Fig. 2](#f0010){ref-type="fig"}B). The other causative mutation, D109H, is predicted to maintain a hydrogen bond to Y122 but not ionic interactions with arginine residues R107 and R120. Instead, it frequently forms a hydrogen bond with adjacent residue E110 from the same monomer ([Fig. 2](#f0010){ref-type="fig"}C). The ionic interactions between residues R107-D80′-R120′ are preserved however lack the stabilizing negative charge from D109. The whole structure of the oligomer is less stable than WT since some of the β-sheets are unfolded. The identified mutation, D109A, is predicted to lead to additional unfolding of β-sheets. Number of residues participating in b-sheets, which form the core of CRYAB, diminished by \> 10% compared to reduction by 4% for D109H. In consequence, the contact between monomers decreases, making the oligomer less stable. Since a side chain of A109 cannot participate in the hydrogen bonds as well as in ionic interactions with any adjacent residues, the triple interaction R107-D80′-R120′ is less stable. Hence, in some interfaces between monomers a disintegration of the triple interaction into two pair interactions (E106-R107 and D80′-R120′) was observed. As a result, CRYAB monomers lose the contact with each other ([Fig. 2](#f0010){ref-type="fig"}D). Not all interfaces change to the same extent in the same time as this is a statistical process, so it seems that changes start in one particular interface and then, possibly due to a resonance effect in the β-barrel, they are distributed to other interfaces via weakening them.

4. Discussion {#s0080}
=============

We have presented a case of the first Polish patient with a clinical and morphological diagnosis of MFM, carrying a novel dominant mutation in the *CRYAB* gene. Using bioinformatic tools, we propose a putative model presenting effects of the D109A mutation on the protein structure and function.

First, using WES approach we have identified in the proband eight putative causative or phenotype-modifying genetic variants. SNVs and indels that passed initial filtering are listed in [Table 1](#t0005){ref-type="table"}. Out of these variants only D109A mutation matches the clinical and morphological phenotype of the proband characteristic for crystallinopathies described so far [@bb0160]. Variants identified within *TTN* (affecting Ig-like domains 28 and 31) though predicted to have a moderate impact do not match the symptoms, as TTN-causative myopathy are known to have early-late adulthood onset and early respiratory insufficiency associated with the titin-associated subtype of MFM [@bb0160]. Also, the *TRAPPC11* variant does not seem to be pathogenic as mutations within this gene cause a myopathy with intellectual disability as well as with fatty liver and infantile cataract which are not the case here [@bb0165], [@bb0170]. Variants identified in *ZFYVE26* also seem not to be pathogenic as known ZFYVE26 mutations are associated with complicated hereditary spastic paraparesis and autophagy [@bb0175]. The same is the case of *NIPA1* and *SPG11* variants, as abnormalities within both proteins are known to be associated with hereditary spastic paraplegia [@bb0180]. However, it is possible that aforementioned variants could affect the course of the disease, worsening the proband condition.

Most of the myopathy-associated mutations described so far (D109H, R120G, Q151X, G154S, P155Rfs9X, R157H) were found in the ACD [@bb0040]. Besides myopathy, mutations D109H, R120G and X176Wfs19X are so far the only ones associated with signs of cardiomyopathy and cataract or discrete lens opacities [@bb0035]. Other recessive (e.g. R11C, R12C, R56W), and dominant (R11H, P20R, P20S, R69C, D140N, K150Nfs34X, A171T) *CRYAB* mutations associated with congenital cataract were also described, uniformly scattered all over the coding sequence [@bb0185].

D109 residue is located in the core domain between β3 (75-83) and FISREFHR motif (113--120, see [Table 2](#t0010){ref-type="table"}). D109 residue is adjacent to 113-120 sequence important for microtubule assembly and aggregation prevention [@bb0190].

The first identified mutation in this residue (D109H) is responsible for autosomal dominant multisystemic phenotype, not only with myopathic features, but also with cardiomyopathy and lens cataract [@bb0195]. Previously, it was shown that D109H mutant protein can enhance protein aggregation and cell apoptosis in the HeLa cells [@bb0200]. This explains well the mechanism of *CRYAB* mutations associated with myopathy and decreased lens transparency, and also the involvement of CRYAB expression in tauopathies [@bb0205]. In muscle, mutated CRYAB binds stronger to desmin and instead of facilitating formation of intermediate filament network, it promotes aggregation of both proteins [@bb0210]. In our study, such CRYAB stained large aggregates as well as desmin-derived electron dense material were found in the proband\'s muscle (see [Fig. 1](#f0005){ref-type="fig"}D-F).

Involvement of CRYAB in the regulation of intracellular apoptotic signals and inhibition of apoptosis through activation of Akt pathway and enhancing PI3K activity [@bb0215], [@bb0220]; could also easily explain not only *CRYAB* mutations in myopathy [@bb0225], but also *CRYAB* overexpression in some types of cancer [@bb0230].

Previous reports on D109H and R120G mutations, both associated with a multisystemic phenotype, suggested that residues D109 and R120 interact with each other during dimerization of CRYAB [@bb0195]. For a better delineation of molecular interactions between the mutated residues and their immediate surrounding we performed molecular dynamics simulations.

We have shown in more detail that D109 is a part of a network of intramolecular interactions with residues within same monomer and adjacent monomers, strengthening the hexamer structure. The D109H mutation decreases the stability of oligomer since H109 interacts with less residues. Some of the β-sheets, which form the core of CRYAB, are unfolded. Likewise the D109A mutation cannot stabilize interaction with adjacent monomer of CRYAB and the β-sheets of this protein are even additionally unfolded, as compared to D109H. In consequence CRYAB monomers lose the contact with each other.

Our results are consistent with and strengthen the previously published results, showing that CRYAB interactions, also with a variety of target proteins, depend on weak non-covalent interplay between a number of bioactive sequences scattered all over the CRYAB sequence and forming a network of highly sensitive areas for protein--protein interactions [@bb0235]. Interestingly, the mutated residue studied herein (D109) is located in the HGKHEERQDE sequence, which is one of the most effective inhibitors of amyloid-beta (Aβ) fibril formation [@bb0235], [@bb0240], [@bb0245]. This motif is located not in the monomer-monomer interface but in the second row (2nd β-thread in β-sheet). Since 3rd β-thread is about a half-length of previous ones, the whole motif is open to water solution and hence exposed to additional oligomerization. D109 is located at the end of 2nd β-thread close to β-turn linking to 1st β-thread. Therefore, the identified mutation D109A destabilizes not only the interface between monomers so the whole oligomer loses its stability, but also, due to the modified sequence motif, makes it more prone to fibril formation. This is particularly important, as the distal parts of this sequence (i.e.: HEER and RQDE) were shown to enhance fibril formation of Aβ [@bb0235], [@bb0240], [@bb0245] As native CRYAB is protective against aggregation of lens crystallins in aging cataract, it could be speculated that D/A and D/H substitutions in position 109 diminish the native functional role of the whole HGKHEERQDE sequence [@bb0250]. These predictions were confirmed by immunostaining for CRYAB of the proband\'s biopsied muscle that showed the presence of large aggregate-like structures distributed not only at the fiber periphery but also within the fiber.

Therefore, we suggest two ways of explaining the pathogenic mechanism of the D109A mutation. First, the mutation may cause aggregation of other proteins including lens crystallins and muscular desmin via dominant negative effect on the chaperone function of oligomeric CRYAB complexes with other partners (including other HSPB family members), leading to insufficient prevention of aggregation of other proteins. Alternatively, the structural instability and propensity to aggregate of the mutated CRYAB itself results in gain-of-function i.e. formation of the visible CRYAB aggregates.

The molecular differences between both mutations (D109A and D109H) cannot be directly translated into differences in clinical phenotypes of affected individuals. It could be speculated that CRYAB oligomeric structures of diverged stability display disturbed interaction with the same protein partners, resulting in common clinical symptoms. The phenotypic diversity has been related to the different interactions between target proteins, including members of the HSPB family with individual CRYAB mutated residues impairing hetero-oligomeric complexes resulting in differently impaired chaperoning functions towards different substrates [@bb0255]. However, in the case of D109A mutation we observed a minor intrafamiliar variability in the clinical phenotype and the age of onset (30--50 years), however with homogenous dominant features involving muscular, cardiac and ocular systems.

In conclusion, this is a first report of a Polish patient presenting with crystallinopathy and multisystemic involvement. According to the co-segregation within a family and *in silico* analyses, the *CRYAB* D109A mutation may be assumed pathogenic [@bb0260]. Molecular modeling in accordance with muscle biopsy microscopic analyses and the clinical data predicted that D109A influence both structure and function of CRYAB due to decreased stability of oligomers leading to aggregate formation. In consequence disrupted sarcomere cytoskeleton organization might lead to muscle pathology. Additionally, impaired CRYAB chaperone-like activity due to mutated RQDE sequence, could promote aggregation of lens crystallins [@bb0250].

The following are the supplementary data related to this article.Suppl. Fig. 1Pedigree diagram of the proband\'s family. The arrow points to the proband.Suppl. Fig. 1.Suppl. Table 1Clinical phenotype of the affected family members.Suppl. Table 1.
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